Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

Global hypertrophic cardiomyopathy therapeutics market overview

According to Technavio’s analyst, the global hypertrophic cardiomyopathy therapeutics market is anticipated to grow at a steady rate and post a CAGR of close to 2% during the forecast period. The high rate of adoption of sedentary lifestyle will drive the growth prospects for the global hypertrophic cardiomyopathy therapeutics market until the end of 2021. It has been observed that the rising adoption of sedentary lifestyles and poor diet increases the prevalence of cardiovascular disease (CVDs) in the developed and developing countries. Consequently, the demand for hypertrophic cardiomyopathy treatment increases with the rising prevalence of CVDs to improve heart muscle disease, heart function, and blood flow, which, in turn, will fuel the hypertrophic cardiomyopathy therapeutics market growth in the coming years.

The advent of genomic medicines will drive the growth prospects for the global hypertrophic cardiomyopathy therapeutics (HCM) market for the next four years. It has been observed that HCM provides an edge to genomic medicines because the genetic screening of HCM includes diagnostics for genomic markers that provides a tailored treatment approach, which, in turn, will propel the hypertrophic cardiomyopathy therapeutics market value.

Competitive landscape and key vendors

The global HCM drugs market is highly competitive and diversified due to the presence of a large number of regional and international vendors across the globe. It has been observed that these vendors are increasingly competing against each other based on factors such as dedicated research units, emerging indications or applications, and collaborations.

Key vendors in this market are -

• AstraZeneca
• Merck
• Pfizer
• Sanofi

Other prominent vendors in the market include Gilead Sciences, Novartis, and Teva Pharmaceutical Industries.

Segmentation by drug class and analysis of the hypertrophic cardiomyopathy therapeutics market

• Calcium channel blockers
• Beta-adrenergic blockers
• Antiarrhythmic
• Anticoagulants

The global calcium channel blockers segment accounted for the majority market share during 2016 and will continue to dominate the market for the next four years. One of the major factors responsible for the market segment's growth is the selective nature of the agents in producing lusitropic and vasodilating effects on smooth muscles of the heart.

Segmentation by geography and analysis of the hypertrophic cardiomyopathy therapeutics market

• Americas
• APAC
• EMEA

In terms of geography, the Americas accounted for the majority market share during 2016 and will continue to dominate the market during the forecasted period. Some of the major factors responsible for the market's growth in the region is the increasing number of investments in research and developmental activities and dedicated manufacturing units to support the research and development of drugs targeting genetic CVDs.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global hypertrophic cardiomyopathy therapeutics market?
• What are the key market trends impacting the growth of the global hypertrophic cardiomyopathy therapeutics market?
• What are the challenges to market growth?
• Who are the key vendors in the global hypertrophic cardiomyopathy therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global hypertrophic cardiomyopathy therapeutics market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global hypertrophic cardiomyopathy therapeutics market?

Technavio also offers customization on reports based on specific client requirement.